Thrivent Financial for Lutherans
NRIX icon

Thrivent Financial for Lutherans’s Nurix Therapeutics NRIX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,177
Closed -$135K – 2512
2023
Q1 		$135K Hold
15,177
– – ﹤0.01% 2401
2022
Q4 		$167K Hold
15,177
– – ﹤0.01% 2369
2022
Q3 		$198K Hold
15,177
– – ﹤0.01% 2344
2022
Q2 		$192K Buy
+15,177
New +$172K ﹤0.01% 2360

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Thrivent Financial for Lutherans's NRIX Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Nurix Therapeutics (NRIX) in Q2 2023, closing a stake of 15,177 shares — an estimated $135K sold.

Thrivent Financial for Lutherans first reported a position in NRIX in Q2 2022 and held it in 4 quarters. The position peaked at $198K in Q3 2022. 126 funds tracked by Wall St. Rank hold NRIX as of Q2 2023.

  • Thrivent Financial for Lutherans reported no remaining Nurix Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 15,177 Nurix Therapeutics shares in Q2 2023, an estimated $135K.
  • Thrivent Financial for Lutherans first reported a position in Nurix Therapeutics in Q2 2022 and held it in 4 quarters.
  • Thrivent Financial for Lutherans's Nurix Therapeutics position peaked at $198K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.